Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics
or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of
pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. In
vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with
substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel
blockers, and HMGCoA reductase inhibitors are not to be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics
or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Studies in man suggest
no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. In vitro studies have shown
no inhibition of any subtype of cytochrome P450. Interactions with substances metabolised by these
enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase
inhibitors are not to be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics
or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of
pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4.
In vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with
substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel
blockers, and HMGCoA reductase inhibitors are not to be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics
or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin. Co-administration of
pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4.
In vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with
substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel
blockers and HMGCoA reductase inhibitors, are not to be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2022-09-09T12:31:00Z · SHA-256 cbd1851f0d7bf897be948ef8b74484626964929eb5e4c45499b1be3f0ce7ae66 · Passage 5732254378306b19997b260af08f91b3f268e2c4a18e75dd538352d92da57c0e · Zeichen 1289–1935 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.